JP2015535241A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535241A5
JP2015535241A5 JP2015538829A JP2015538829A JP2015535241A5 JP 2015535241 A5 JP2015535241 A5 JP 2015535241A5 JP 2015538829 A JP2015538829 A JP 2015538829A JP 2015538829 A JP2015538829 A JP 2015538829A JP 2015535241 A5 JP2015535241 A5 JP 2015535241A5
Authority
JP
Japan
Prior art keywords
decline
salt
brain function
agent
ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535241A (ja
JP6166786B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2015538829A priority Critical patent/JP6166786B2/ja
Priority claimed from JP2015538829A external-priority patent/JP6166786B2/ja
Publication of JP2015535241A publication Critical patent/JP2015535241A/ja
Publication of JP2015535241A5 publication Critical patent/JP2015535241A5/ja
Application granted granted Critical
Publication of JP6166786B2 publication Critical patent/JP6166786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538829A 2012-10-30 2013-10-30 脳機能低下の予防または改善剤 Active JP6166786B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015538829A JP6166786B2 (ja) 2012-10-30 2013-10-30 脳機能低下の予防または改善剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012238542 2012-10-30
JP2012238542 2012-10-30
JP2015538829A JP6166786B2 (ja) 2012-10-30 2013-10-30 脳機能低下の予防または改善剤
PCT/JP2013/080053 WO2014069667A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (3)

Publication Number Publication Date
JP2015535241A JP2015535241A (ja) 2015-12-10
JP2015535241A5 true JP2015535241A5 (https=) 2016-12-15
JP6166786B2 JP6166786B2 (ja) 2017-07-19

Family

ID=50627559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538829A Active JP6166786B2 (ja) 2012-10-30 2013-10-30 脳機能低下の予防または改善剤

Country Status (9)

Country Link
US (2) US10905705B2 (https=)
EP (1) EP2914270B1 (https=)
JP (1) JP6166786B2 (https=)
AU (1) AU2013339058B2 (https=)
CA (1) CA2889109C (https=)
ES (1) ES2906614T3 (https=)
NZ (1) NZ707081A (https=)
PL (1) PL2914270T3 (https=)
WO (1) WO2014069667A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US11583546B2 (en) * 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function
US11186605B2 (en) 2016-10-06 2021-11-30 Kyowa Hakko Bio Co., Ltd. Crystal of cytidine diphosphate choline and production method thereof
JP7142284B2 (ja) * 2017-06-06 2022-09-27 株式会社らいむ 神経伸長促進剤
JP2019218284A (ja) * 2018-06-18 2019-12-26 オンガネジャパン株式会社 若齢者学習能力向上のための経口組成物及び若齢者の学習能力を向上させる方法
WO2025258678A1 (ja) * 2024-06-13 2025-12-18 キリンホールディングス株式会社 神経回路の興奮を促進するための組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT813416E (pt) * 1995-03-06 2005-10-31 Interneuron Pharma Reducao do volume de enfarte usando citicolina
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
WO2009096505A1 (ja) * 2008-01-30 2009-08-06 Kyowa Hakko Bio Co., Ltd. 注意集中力向上剤
CN102316852A (zh) * 2009-02-11 2012-01-11 丽卡实验有限公司 脂质胞二磷胆碱注射液
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function

Similar Documents

Publication Publication Date Title
JP2015535241A5 (https=)
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2016066744A3 (en) Gip agonist compounds and methods
DK3313991T3 (da) Modificeret faktor ix og sammensætninger, fremgangsmåder og anvendelser til genoverførsel til celler, organer og væv
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
JP2012143233A5 (https=)
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2015061632A3 (en) Antimicrobial compositions and articles
WO2015069697A3 (en) Combination therapy
JP2014530176A5 (https=)
NZ707081A (en) Agent for preventing or improving decline in brain function
WO2015026494A3 (en) Methods for treating tissue fibrosis
WO2015017338A3 (en) Treatment of beverages to reduce the effects of noxious constituents
JP2013533867A5 (https=)
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
JP2012217972A5 (https=)
WO2014165713A3 (en) Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
MX378190B (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.
Wahyudi et al. Predicting the unpredictable: Recent structure–activity studies on peptide-based macrocycles
JP2017531030A5 (https=)
BR112015028752A2 (pt) micro- ou nanopartículas antimicrobianas compreendendo um sal de clorexidina, método de produção e usos das mesmas
HRP20161135T1 (hr) Oblici u krutom stanju n-((s)-2,3-dihidroksi-propil)-3-(2-fluoro-4-jodo-fenilamino)-izonikotinamida